Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?
Portfolio Pulse from Vandana Singh
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) stock hit a 52-week low after announcing the continuation of the Phase 3 RAISE trial for IV ganaxolone in treating refractory status epilepticus, with results expected in summer 2024. The company remains committed to its development plans, including the Phase 3 TrustTSC trial for Ztalmy, with topline results due in Q4 2024. Preliminary Q1 2024 revenue is between $7.4 and $7.6 million, with cash reserves of $113.3 million. Cost reduction strategies are being evaluated to extend the cash runway.
April 15, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Marinus Pharmaceuticals' stock hit a 52-week low following the announcement to continue the Phase 3 RAISE trial for IV ganaxolone, with results expected in summer 2024.
The stock's decline to a 52-week low reflects investor concerns over the continuation of the RAISE trial without meeting early stopping criteria, indicating potential uncertainty about the trial's outcome and future profitability.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100